Overview A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC Status: Not yet recruiting Trial end date: 2022-03-31 Target enrollment: Participant gender: Summary The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without famitinib in patients with advanced or metastatic NSCLC Phase: Phase 2 Details Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.